The Serena 6 trial's PFS2 data is difficult to interpret because only 13% of the control arm received a next-generation oral SERD post-progression. This low crossover rate makes it hard to definitively conclude if switching to camazestrant early is superior to switching later, as the control group's subsequent treatment was not the modern standard of care.
The Serena 6 trial pioneers a shift from reacting to visible tumor growth to proactively treating molecular signals. By intervening upon detection of an ESR1 mutation—before radiographic progression—the study suggests this approach can improve quality of life and delay disease advancement, challenging the current standard of care.
In the Serena 6 trial, patients whose circulating tumor DNA (ctDNA) was cleared after switching to camazestrant had a significantly improved overall survival (HR 0.4). This exploratory finding suggests ctDNA monitoring can be a potent early indicator of long-term treatment success, potentially reshaping how therapeutic efficacy is measured long before imaging can.
The Victoria 1 study showed that adding a CDK4/6 inhibitor (triplet therapy) improved outcomes only in patients with PIK3CA wild-type tumors. In PIK3CA-mutant tumors, the doublet therapy was equally effective. This surprising finding highlights that distinct resistance mechanisms are at play and that mutation status is critical for selecting optimal combination regimens.
The Victoria 1 trial reported "historically low" discontinuation rates for the PI3K inhibitor alpelisib. This indicates that oncologists have become significantly better at proactively managing the drug's known toxicities, such as hyperglycemia. This real-world clinical maturation has improved the drug's tolerability and practical utility since its initial approval studies.